Last Updated : August 15, 2019
Details
Generic Name:
ibrutinib
Project Status:
Not filed
Therapeutic Area:
Chronic graft versus host disease
Manufacturer:
Janssen Canada Inc.
Brand Name:
Imbruvica
Project Line:
Reimbursement Review
Project Number:
NS0009-000
Submission Type:
Non Submission
Fee Schedule:
N/A
Indications:
Chronic graft versus host disease
Recommendation Type:
Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer
Last Updated : August 15, 2019